The FDA Has Approved Pfizer's Braftovi (Encorafenib) + Mektovi (Binimetinib) For Metastatic Non-small Cell Lung Cancer With A BRAF V600E Mutation
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Pfizer's Braftovi (Encorafenib) + Mektovi (Binimetinib) for metastatic non-small cell lung cancer with a BRAF V600E mutation.
October 12, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's Braftovi and Mektovi have been approved by the FDA for treating metastatic non-small cell lung cancer. This could potentially increase Pfizer's revenues.
The FDA approval of Pfizer's Braftovi and Mektovi for treating metastatic non-small cell lung cancer could potentially increase the company's revenues as it opens up a new market for these drugs. This is likely to have a positive impact on Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100